|1.||Nakamichi, Keiko: 1 article (12/2014)|
|2.||Yoshida, Naoyuki: 1 article (12/2014)|
|3.||Hashimoto, Takashi: 1 article (12/2014)|
|4.||Hatayama, Yuki: 1 article (12/2014)|
|5.||Hatayama, Y: 1 article (04/2014)|
|6.||Nakamichi, K: 1 article (04/2014)|
|7.||Kohayakawa, H: 1 article (04/2014)|
|8.||Hashimoto, T: 1 article (04/2014)|
|9.||Yoshida, N: 1 article (04/2014)|
|10.||Kiyoshi, T: 1 article (04/2014)|
|1.||Alzheimer Disease (Alzheimer's Disease)
04/18/2014 - "These findings indicate that AC-3933 with its low risk for side effects may be useful in the treatment of Alzheimer's disease. "
04/18/2014 - "In this study, we evaluated AC-3933 potential for the treatment of Alzheimer's disease, a disorder characterized by progressive decline mainly in cholinergic function. "
04/18/2014 - "In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's disease."
|2.||Memory Disorders (Memory Loss)
12/15/2014 - "In scopolamine-treated mice, both AC-3933 and donepezil significantly ameliorated memory deficits in the Y-maze test at doses of 0.3-3 mg/kg and 10-15 mg/kg, respectively. "
12/15/2014 - "We have previously reported that AC-3933, a newly developed benzodiazepine receptor partial inverse agonist, facilitates acetylcholine release in the hippocampus and ameliorates scopolamine-induced memory deficits in rats. "
|3.||Amnesia (Dissociative Amnesia)
|2.||GABA-A Receptors (GABA(A) Receptor)
|3.||Acetylcholine (Acetylcholine Chloride)